从2003年到2022年,对瘤微环境中的代谢重编程进行了图书统计分析
Yupeng Xi1, Rui Liu2, Xing Zhang2
1Department of General Internal Medicine, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Cancer reports (Hoboken, N.J.)
|August 19, 2024
概括
本文献分析揭示了瘤微环境 (TME) 和代谢重编程研究的关键趋势. 美国在出版物方面处于领先地位,免疫代谢和与瘤相关的巨细胞是新兴热门话题.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 代谢研究研究 代谢研究
背景情况:
- 癌症免疫疗法面临局限性,部分原因是瘤微环境 (TME) 相互作用的抵抗机制.
- 在TME内的代谢重编程显著影响抗瘤免疫力.
- 有限的研究已经全面探索了TME和代谢重编程的交叉点.
研究的目的:
- 进行对代谢重编程和TME研究的文献分析.
- 确定20年 (2003-2022) 期间的当前研究状况,热门话题和趋势.
主要方法:
- 搜索科学网络核心集合的相关研究.
- 使用了包括Bibliometrix,VOSviewer和CiteSpace在内的图书识别和视觉分析工具.
- 分析了出版趋势,引用数量,合作网络和关键词集群.
主要成果:
- 在2003年至2022年期间,共发表了4726篇文章,显示出年增长.
- 美国是该研究领域的领先国家.
- 关键的研究集群包括TME,代谢重编程,免疫代谢和免疫,最近的重点是免疫代谢,糖解,免疫细胞和与瘤相关的巨细胞.
结论:
- 本研究提供了对代谢重编程和TME研究的全面概述.
- 强调了TME中免疫代谢的重要性日益增加.
- 建议跨学科的方法在这个有前途的领域未来的研究.
相关概念视频
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


